A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Inclusion Criteria:

• Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG)

• Study participant is willing to perform and capable of performing homeself-administration

• Study participant is considered by the investigator for additional rozanolixizumabtreatment with the posology proposed in this study.

• Body weight ≥35 kg

• Study participants may be male or female

Exclusion Criteria:

• Study participant has a known hypersensitivity to other anti-Fc receptor (FcRn)medications, to any components of the study medication, to any of the excipients (including polysorbate 80), or has a known history of hyperprolinemia, since bothpolysorbate 80 and L-proline are constituents of the rozanolixizumab formulation

• Study participant with a known tuberculosis (TB) infection, at high risk ofacquiring TB infection, or latent tuberculosis infection (LTBI), or current orhistory of nontuberculous mycobacterial infection (NTMBI)

• Study participant has a clinically relevant active infection or a history of seriousinfection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline Visit

• The study participant previously participated in any rozanolixizumab MG study andmet any mandatory withdrawal criteria (unless the reason is directly related toMG0020 participation) or mandatory study drug discontinuation criteria.

• Study participant has received a live vaccination within 4 weeks before startingtreatment, or a Bacillus Calmette-Guérin (BCG) vaccine within 1 year before startingtreatment; or intends to have a live vaccination during the course of the study orwithin 8 weeks following the last dose of rozanolixizumab

• Study participant with severe (defined as Grade 3 on the Myasthenia GravisActivities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal orrespiratory muscles, or who has myasthenic crisis or impending crisis